| Literature DB >> 27478483 |
Cassiana Macagnan Viau1, Dinara Jaqueline Moura2, Pricila Pflüger3, Valdir Alves Facundo4, Jenifer Saffi1.
Abstract
Combretum leprosum Mart., a member of the Combretaceae family, is a traditionally used Brazilian medicinal plant, although no evidence in the literature substantiates its antioxidant action and the safety of its use. We evaluated the antioxidant properties of the ethanolic extract (EE) from flowers of C. leprosum and its isolated products 5,3'-dihydroxy-3,7,4'-trimethoxyflavone (FCL2) and 5,3',4'-trihydroxy-3,7-dimethoxyflavone (FCL5) in Saccharomyces cerevisiae strains proficient and deficient in antioxidant defenses. Their mutagenic activity was also assayed in S. cerevisiae, whereas cytotoxic and genotoxic properties were evaluated by MTT and Comet Assays, respectively, in V79 cells. We show that the EE, FCL2, and FCL5 have a significant protective effect against H2O2. FCL2 showed a better antioxidant action, which can be related to the activation of the 3'-OH in the presence of a methoxyl group at 4' position in the B-ring of the molecule, while flavonoids did not induce mutagenesis in yeast, and the EE was mutagenic at high concentrations. The toxicity of these compounds in V79 cells increases from FCL2 = FCL5 < EE; although not cytotoxic, FCL5 induced an increase in DNA damage. The antioxidant effect, along with the lower toxicity and the absence of genotoxicity, suggests that FCL2 could be suitable for pharmacological use.Entities:
Year: 2016 PMID: 27478483 PMCID: PMC4949345 DOI: 10.1155/2016/9849134
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Chemical structures of FCL2 (5,3′-dihydroxy-3,7,4′-trimethoxyflavone) and FCL5 (5,3′,4′-trihydroxy-3,7-dimethoxyflavone) products isolated from the flowers of Combretum leprosum.
Saccharomyces cerevisiae strains used in this study.
| Strain | Genotype | Enzymatic defense lacking | Source |
|---|---|---|---|
| EG103 (SOD-WT) |
| None | E. Grallaa |
| EG118 ( |
| Cu-Zn SOD (cytosolic) | E. Grallaa |
| EG110 ( |
| Mn SOD (mitochondrial) | E. Grallaa |
| EG133 ( |
| Both SODs | E. Grallaa |
| XV185-14c (WT) |
| None | von Borstel et al. (1971)b |
aDepartment of Chemistry and Biochemistry, University of California, Los Angeles, CA 90024-1569, USA.
bReference [54].
Cytotoxicity and antioxidant effect of C. leprosum ethanolic extract in S. cerevisiae.
| Treatment | Yeast strains | |||
|---|---|---|---|---|
| WT |
|
|
| |
| NCa | 100.0 ± 0.0 | 100.0 ± 0.0 | 100.0 ± 0.0 | 100.0 ± 0.0 |
|
| 99.33 ± 2.52 | 89.60 ± 0.95 | 100.97 ± 3.65 | 96.00 ± 3.61 |
|
| 99.67 ± 4.73 | 80.93 ± 3.66 | 98.57 ± 0.67 | 94.27 ± 3.95 |
|
| 94.63 ± 4.46 | 76.43 ± 10.64 | 94.53 ± 4.17 | 90.67 ± 0.71 |
|
| 87.23 ± 2.25 | 67.50 ± 2.12 | 96.83 ± 3.33 | 89.63 ± 1.05 |
| PCb: H2O2 5 mM | 63.03 ± 4.12 | 16.27 ± 4.88 | 19.10 ± 4.03 | 19.33 ± 2.10 |
|
| 68.53 ± 1.40 | 28.3 ± 6.65 | 31.45 ± 2.19 | 25.70 ± 2.97 |
|
| 68.33 ± 7.16 | 43.85 ± 2.90 | 38.35 ± 2.19 | 41.25 ± 1.91 |
|
| 70.80 ± 2.21 | 41.65 ± 2.76 | 41.50 ± 3.96 | 46.70 ± 4.10 |
|
| 71.40 ± 5.94 | 34.90 ± 5.66 | 38.0 ± 7.49 | 35.30 ± 6.51 |
aNC: negative control (solvent: DMSO).
bPositive control (H2O2). Data significant in relation to oxidant-treated samples at P < 0.01 and P < 0.001/one-way ANOVA, Tukey's multiple comparison test.
Cytotoxicity and antioxidant effect of FCL2 product isolated from C. leprosum ethanolic extract in S. cerevisiae.
| Treatment | Yeast strains | |||
|---|---|---|---|---|
| WT |
|
|
| |
| NCa | 100.0 ± 0.0 | 100.0 ± 0.0 | 100.0 ± 0.0 | 100.0 ± 0.0 |
| FCL2 10 | 97.3 ± 1.98 | 94.05 ± 6.43 | 98.80 ± 1.56 | 96.50 ± 0.85 |
| FCL2 50 | 98.05 ± 2.62 | 94.65 ± 3.89 | 95.10 ± 2.26 | 96.25 ± 1.91 |
| FCL2 100 | 96.90 ± 4.24 | 93.60 ± 4.38 | 96.40 ± 4.95 | 97.10 ± 1.13 |
| FCL2 500 | 93.70 ± 1.13 | 94.80 ± 1.27 | 96.05 ± 3.75 | 97.80 ± 2.97 |
| PCb: H2O2 5 mM | 63.03 ± 4.12 | 16.27 ± 4.88 | 19.10 ± 4.03 | 19.33 ± 2.10 |
| FCL2 10 | 63.15 ± 10.25 | 31.60 ± 2.40 | 39.10 ± 1.13 | 33.20 ± 2.95 |
| FCL2 50 | 68.95 ± 1.06 | 38.0 ± 2.12 | 42.80 ± 2.97 | 66.53 ± 5.75 |
| FCL2 100 | 71.15 ± 1.77 | 41.60 ± 5.52 | 44.0 ± 2.55 | 75.15 ± 2.90 |
| FCL2 500 | 71.10 ± 3.11 | 35.80 ± 7.50 | 31.35 ± 2.76 | 66.05 ± 7.71 |
aNC: negative control (solvent: DMSO).
bPositive control (H2O2). Data significant in relation to oxidant-treated samples at P < 0.05, P < 0.01, and P < 0.001/one-way ANOVA, Tukey's multiple comparison test.
Cytotoxicity and antioxidant effect of FCL5 product isolated from C. leprosum ethanolic extract in S. cerevisiae.
| Treatment | Yeast strains | |||
|---|---|---|---|---|
| WT |
|
|
| |
| NCa | 100.0 ± 0.0 | 100.0 ± 0.0 | 100.0 ± 0.0 | 100.0 ± 0.0 |
| FCL5 10 | 99.65 ± 3.32 | 99.35 ± 0.78 | 98.20 ± 1.98 | 93.75 ± 5.44 |
| FCL5 50 | 98.15 ± 2.33 | 99.40 ± 3.82 | 94.0 ± 5.37 | 92.20 ± 4.95 |
| FCL5 100 | 95.05 ± 0.64 | 96.80 ± 1.56 | 93.35 ± 4.88 | 92.25 ± 0.64 |
| FCL5 500 | 97.25 ± 3.61 | 93.65 ± 1.63 | 87.55 ± 1.20 | 83.30 ± 3.68 |
| PCb: H2O2 5 mM | 63.03 ± 4.12 | 16.27 ± 4.88 | 19.10 ± 4.03 | 19.33 ± 2.10 |
| FCL5 10 | 68.05 ± 3.04 | 29.90 ± 0.28 | 38.30 ± 9.33 | 35.20 ± 2.40 |
| FCL5 50 | 70.55 ± 2.48 | 36.70 ± 4.53 | 43.80 ± 1.41 | 45.10 ± 3.96 |
| FCL5 100 | 69.50 ± 5.52 | 42.35 ± 3.04 | 42.20 ± 4.38 | 51.25 ± 6.29 |
| FCL5 500 | 68.15 ± 3.75 | 29.50 ± 1.70 | 35.25 ± 5.16 | 29.85 ± 1.49 |
aNC: negative control (solvent: DMSO).
bPositive control (H2O2). Data significant in relation to oxidant-treated samples at P < 0.05, P < 0.01, and P < 0.001/one-way ANOVA, Tukey's multiple comparison test.
Induction of reversion of point mutation for his1-798, ochre allele lys1-1, and frameshift mutation (hom3-10) in S. cerevisiae haploid strain XV185-14c after treatment with FCL2 isolated product from ethanolic extract of C. leprosum.
| Agent | Treatment ( | Survival (%) | LYS1/108 survivorsb | HIS1/107 survivorsa | HOM3/108 survivorsa |
|---|---|---|---|---|---|
| STAT cells treated in PBS | |||||
| NCd | 0 | 100.00 | 4.00 ± 2.83c | 10.50 ± 0.71c | 4.0 ± 1.41c |
| 4-NQOe | 1.0 | 39.97 | 20.85 ± 2.48 | 49.50 ± 9.19 | 13.50 ± 4.95 |
| FCL2 | 10 | 98.00 | 4.00 ± 1.41 | 10.25 ± 1.77 | 6.00 ± 1.42 |
| 50 | 93.03 | 5.50 ± 2.12 | 13.15 ± 1.20 | 5.00 ± 2.83 | |
| 100 | 81.70 | 7.50 ± 2.12 | 10.20 ± 4.24 | 5.00 ± 1.44 | |
| 500 | 82.50 | 8.50 ± 0.71 | 10.65 ± 6.29 | 3.50 ± 2.12 |
aLocus-specific revertants. bLocus nonspecific revertants. cMean and standard deviation per three independent experiments. dNegative control (solvent). ePositive control. Data significant in relation to negative control group (solvent) at P < 0.01; P < 0.001/one-way ANOVA, Tukey's multiple comparison test.
Induction of reversion of point mutation for his1-798, ochre allele lys1-1, and frameshift mutation (hom3-10) in S. cerevisiae haploid strain XV185-14c after treatment with FCL5 isolated product from ethanolic extract of C. leprosum.
| Agent | Treatment ( | Survival (%) | LYS1/108 survivorsb | HIS1/107 survivorsa | HOM3/108 survivorsa |
|---|---|---|---|---|---|
| STAT cells treated in PBS | |||||
| NCd | 0 | 100.00 | 4.00 ± 2.83c | 10.50 ± 0.71c | 4.0 ± 1.41c |
| 4-NQOe | 1.0 | 39.97 | 20.85 ± 2.48 | 49.50 ± 9.19 | 13.50 ± 4.95 |
| FCL5 | 10 | 89.60 | 3.27 ± 2.13 | 7.49 ± 0.71 | 4.46 ± 3.17 |
| 50 | 85.67 | 6.94 ± 0.55 | 10.24 ± 2.10 | 4.78 ± 1.90 | |
| 100 | 92.70 | 6.20 ± 0.29 | 7.50 ± 0.87 | 5.10 ± 0.36 | |
| 500 | 76.57 | 5.95 ± 0.21 | 9.52 ± 3.10 | 7.00 ± 1.27 |
aLocus-specific revertants. bLocus nonspecific revertants. cMean and standard deviation per three independent experiments. dNegative control (solvent). ePositive control. Data significant in relation to negative control group (solvent) at P < 0.01; P < 0.001/one-way ANOVA, Tukey's multiple comparison test.
Induction of reversion of point mutation for his1-798, ochre allele lys1-1, and frameshift mutation (hom3-10) in S. cerevisiae haploid strain XV185-14c after treatment with crude ethanolic extract of C. leprosum.
| Agent | Treatment ( | Survival (%) | LYS1/108 survivorsb | HIS1/107 survivorsa | HOM3/108 survivorsa |
|---|---|---|---|---|---|
| STAT cells treated in PBS | |||||
| NCd | 0 | 100.00 | 4.00 ± 2.83c | 10.50 ± 0.71c | 4.00 ± 1.41c |
| 4-NQOe | 1.0 | 39.97 | 20.85 ± 2.48 | 49.50 ± 9.19 | 13.50 ± 4.95 |
|
| 10 | 94.70 | 7.50 ± 0.71 | 12.25 ± 0.25 | 4.00 ± 2.83 |
| 50 | 91.73 | 8.00 ± 1.41 | 12.50 ± 0.71 | 5.50 ± 2.12 | |
| 100 | 91.73 | 7.50 ± 2.12 | 12 ± 2.83 | 5.00 ± 2.83 | |
| 500 | 88.33 | 10.50 ± 2.12 | 27.00 ± 7.07 | 6.00 ± 2.83 |
aLocus-specific revertants. bLocus nonspecific revertants. cMean and standard deviation per three independent experiments. dNegative control (solvent). ePositive control. Data significant in relation to negative control group (solvent) at P < 0.05; P < 0.001/one-way ANOVA, Tukey's multiple comparison test.
Figure 2Survival of V79 cells after exposure to crude ethanolic extract of Combretum leprosum and FCL2 (5,3′-dihydroxy-3,7,4′-trimethoxyflavone) and FCL5 (5,3′,4′-trihydroxy-3,7-dimethoxyflavone) isolated products.
Figure 3Induction of DNA strand breaks by 3 h treatment with crude ethanolic extract of Combretum leprosum (a) and FCL2 (b) and FCL5 (c) products in V79 cells evaluated by Comet Assay. Mean ± SD of three independent experiments. Significantly different in relation to control damage level; P < 0.01; P < 0.001.